This study is a 3 year multi-center study comparing the safety and efficacy of fingolimod in patients with primary progressive Multiple Sclerosis (PPMS). …
mscenter.med.wayne.edu
This study is a 3 year multi-center study comparing the safety and efficacy of fingolimod in patients with primary progressive Multiple Sclerosis (PPMS). Patients will be randomly assigned to receive a daily tablet of either 0.5 mg fingolimod or placebo (dummy pill).
Eligibility: Patients 25-65 yrs old with PPMS, able to walk at least 100 meters with or without resting, if assistance is needed for walking that assistance may only come from a cane or a crutch.
For more information visit: Novartis PPMS
.
****************************************************************
Know somebody affected by Multiple Sclerosis?
Ask them to remain CURRENT with Multiple Sclerosis news & information
when registered at the MS Views and News website
.Weekly e-Newsletter now reaching (87) Countries. .
***************************************************************************************
Help STUART to Educate: Please donate
– all contributions are tax deductible –
We are a 501c3 – Not for Profit Charity
.
“Providing You with ‘MS Views and News’, is what we do“
***************************************************************************************
.
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews